<DOC>
	<DOCNO>NCT02317549</DOCNO>
	<brief_summary>Septic shock potentially life-threatening condition result multi-organ dysfunction syndrome ( MODS ) mortality . LB1148 formulate preserve gut integrity physiological shock ameliorate subsequent autodigestion lead MODS mortality . The purpose study septic shock patient determine enteral administration LB1148 increase number day alive without cardiovascular , pulmonary renal replacement therapy Day 28 .</brief_summary>
	<brief_title>Treatment Septic Shock Inhibiting Autodigestion Preserving Gut Integrity With Enteric LB1148</brief_title>
	<detailed_description>Primary Objective ( ) : The primary objective study determine enteral administration LB1148 increase number day alive without cardiovascular , renal pulmonary organ support Day 28 . The secondary objective study determine LB1148 : - Reduce mortality Day 7 , Day 28 Day 90 ; - Reduce number day organ dysfunction resolution evidence Sequential Organ Failure Assessment ( SOFA ) score ≤2 patient alive Day 28 ; - Reduce daily organ dysfunction evidence average SOFA score Day 14 Day 28 ; - Reduce number patient new-onset organ dysfunction Day 8 ; - Increase number day alive free renal replacement therapy Day 28 ; - Increase number day alive free renal dysfunction Day 28 ; - Increase number day alive ventilator free Day 28 ; - Increase number day alive free vasopressor Day 14 Day 28 ; - Increase number day alive free liver dysfunction Day 28 ; - Increase number day alive Intensive Care Unit ( ICU ) Day 28 ; - Increase number day alive hospital Day 28 , - Improve patient functional outcome Day 28 evidence EuroQoL EQ 5D questionnaire . In addition , study assess safety tolerability LB1148 patient septic shock . The exploratory objective study determine LB1148 : - Reduce number patient new-onset organ dysfunction Day 9 Day 16 ; - Decrease number day normalize serum lactate ( ≤2.2 mmol/L ) Day 28 ; - Reduce average daily serum lactate level Day 8 ; - Increase number day alive free ileus Day 8 Day 28 .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . First episode ( current hospitalization ) document suspected sepsis peritoneum/abdomen , soft tissue , blood , nonhospital acquire lung origin . 2 . Must receive antimicrobial therapy document suspected infection . 3 . Must septic shock require vasopressor despite adequate fluid resuscitation 30 mL/kg crystalloid colloid equivalent , either SBP ≤90 mmHg MAP ≤65 mmHg ( i.e . must unable maintain adequate blood pressure despite adequate fluid resuscitation without use vasopressor ) . Note : 30 mL/kg crystalloid equivalent 15 mL/kg colloid . 4 . Must requirement vasopressor support adequate fluid resuscitation , , randomization , must require minimum dose least 1 follow vasopressor : Norepinephrine ≥5 µg/min ; Dopamine ≥10 µg/kg/min ; Phenylephrine ≥25 µg/min ; Epinephrine ≥5 µg/min , Vasopressin ≥0.03 units/min . Exclusion Criteria Patients eligible participation study meet ANY follow criterion : 1 . Age &lt; 18 age ≥76 year . 2 . Time elapse since onset shock &gt; 24 hour . Onset shock define first administration vasopressor give continuous infusion ( i.e . single bolus norepinephrine , phenylephrine , ephedrine ) . 3 . Septic shock episode second great episode current hospitalization . Note : patient transfer another healthcare facility still within first 24 hour first episode shock eligible . 4 . Have hospital acquire pneumonia . 5 . Have genitourinary infection cause septic shock . 6 . Unable maintain minimum MAP 60 mmHg despite presence vasopressor IV fluid . Note : brief transient BPs 60 mmHg disqualifying . 7 . Have serum lactate measurement &lt; 2.5 mmol/L adequate fluid resuscitation ( refer Inclusion Criteria # 3 ) . 8 . Not expect survive least 28 day due preexisting , nonshock related medical condition . 9 . Highest total SOFA score ( know staff time randomization ) screen period &lt; 6 . Note : individual organ component subscore calculate high ( bad ) score obtain organ screen period , randomization . 10 . Highest total SOFA score ( know staff time randomization ) screen period &gt; 18 . Note : individual organ component subscore calculate high ( bad ) score obtain organ screen period . 11 . Lack commitment aggressive source control infection . 12 . The patient patient 's surrogate fail voluntarily sign informed consent form ( ICF ) . 13 . Ineligible feed tube placement . 14 . Chronic renal insufficiency require hemodialysis associate current episode sepsis . 15 . Chronic pulmonary dysfunction require mechanical ventilation unrelated current episode sepsis . 16 . Undergoing active radiation cytotoxic chemotherapy treatment uncontrolled malignancy . Note : hormonal surgical therapy permit . 17 . Presence third degree burn involve &gt; 20 % body surface area 7 day prior study entry . 18 . Known inability take study medication ( i.e . complete small bowel obstruction ) . 19 . Has acute meningitis . 20 . Have follow medical condition : HIVpositive patient whose recent CD4 count ≤50/mm3 ; Neutrophils &lt; 1000/mm3 unless due sepsis ; Received chest compression part CPR hospitalization without neurologic recovery ; Poorly control neoplasm ; Endstage lung disease Cystic Fibrosis ; Endstage liver disease ( ChildPugh Class C [ score &gt; 10 ] , evidence portal hypertension esophageal varix ) ; Severe congestive heart failure ( New York Heart Association [ NYHA ] Class IV presepsis ejection fraction &lt; 30 % ) ; Undergone organ transplant ( include bone marrow , heart , lung , liver , pancreas , small bowel transplantation ) , Primary ICU admit diagnosis acute myocardial infarction ( MI ) . 21 . Have relative contraindication take TXA believe adverse risk/benefit ratio take drug . These include patient : Known sensitivity TXA ; Recent craniotomy ( past 28 day ) ; Active cerebrovascular bleed ; Active thromboembolic disease , ( deep vein thrombosis , pulmonary embolism [ PE ] , cerebral thrombosis , ischemic stroke , acute coronary syndrome [ ACS ] ) ; Acute promyelocytic leukemia take alltrans retinoic acid remission induction ; Continuing use combine hormonal contraceptive ( include combine hormonal pill , patch vaginal ring ) . 22 . Exclusion condition , opinion investigator coordinate center , would preclude subject appropriate candidate study . 23 . Received investigational therapy device within 4 week prior Screening . 24 . Female patient childbearing potential positive urine serum pregnancy test taking ( willing take ) acceptable birth control measure ( abstinence , intrauterine device , contraceptive implant barrier method ) Day 28 . Additionally , woman lactate insist breast feeding within 5 day last dose study drug sepsis resolve . Note : postpartum patient persistent positive pregnancy test ( human chorionic gonadotropin [ HCG ] value time decrease ) allow study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>vasodilatory shock</keyword>
	<keyword>circulatory shock</keyword>
	<keyword>Systemic Inflammatory Response Syndrome</keyword>
	<keyword>SIRS</keyword>
	<keyword>infection</keyword>
	<keyword>toxemia</keyword>
	<keyword>gut barrier breakdown</keyword>
	<keyword>autodigestion</keyword>
	<keyword>multiorgan failure</keyword>
	<keyword>MOF</keyword>
	<keyword>multiorgain dysfunction syndrome</keyword>
	<keyword>MODS</keyword>
	<keyword>hyperlactatemia</keyword>
	<keyword>tissue hypoxia</keyword>
</DOC>